Advancing Predictions of Oral Drug Absorption, CYP3A4 Induction, and Transporter-Mediated Interactions Using a Human...

Area of Science:

• Pharmacology
• Drug Development
• In Vitro Models

Background:

• Accurate prediction of human oral drug absorption is critical for efficient drug development.
• Physiologically relevant human in vitro models are needed to improve prediction accuracy.
• Existing models like Caco-2 have limitations in predicting complex drug interactions and absorption.

Purpose of the Study:

• To comprehensively assess the EpiIntestinal™ 3D model for predicting oral absorption (Fa) and intestinal availability (Fg).
• To evaluate the model's capability in predicting CYP3A4 induction and drug-drug interactions (DDIs).
• To compare the predictive performance of EpiIntestinal™ against Caco-2 models.

Main Methods:

• Assessed EpiIntestinal™ for expression of drug-metabolizing enzymes, transporters, and nuclear receptors (e.g., PXR).
• Correlated permeability coefficients with human absorption data for 18 drugs.
• Utilized physiologically based pharmacokinetic (PBPK) modeling with EpiIntestinal™ data to predict Cmax, Fa, and Fg.
• Evaluated CYP3A4 induction and transporter-mediated DDIs using rifampicin and specific drug substrates.

Main Results:

• EpiIntestinal™ demonstrated clinically relevant expression of key drug-metabolizing enzymes and transporters.
• PBPK modeling with EpiIntestinal™ data accurately predicted Cmax for P-gp substrates (digoxin, dabigatran etexilate), outperforming Caco-2.
• The model accurately predicted human Fg for CYP3A4/5 substrates and demonstrated CYP3A4 and P-gp induction by rifampicin.
• Combined EpiIntestinal™ and hepatic model data accurately predicted DDI effects and transporter-mediated DDIs.

Conclusions:

• EpiIntestinal™ shows significant potential for predicting human oral drug absorption (Fa) and intestinal availability (Fg).
• The model effectively predicts CYP3A4 induction and transporter-mediated drug-drug interactions (DDIs).
• EpiIntestinal™ offers a valuable tool for early drug development, improving upon existing in vitro models.